Skip to content
Salmedix logo — Pioneering advanced treatments for blood cancers, delivering...

Salmedix

Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical trials with a focus on patient health and care

Founded 2000 Series C Total: $72.50M Biotechnology, Health Care

General Information

Company Name Salmedix
Founded Year 2000
Industries Biotechnology, Health Care
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Salmedix. To contact Salmedix, visit salmedix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Salmedix compare?

A PDF of Salmedix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Salmedix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Salmedix

Founded in 2000 by David Kabakoff, Salmedix is a pioneer in oncology drug development, focusing on treatments for hematologic malignancies. The company's primary product, SDX-105, has been made available in Germany to address various blood cancers, and is currently undergoing Phase II clinical trials in the U.S. and Canada. Additionally, Salmedix has other clinical-stage product candidates, SDX-101 and SDX-102, which are in Phase II development, backed by substantial prior human clinical experience. The recent $45.00M Series C investment received on 19 October 2005 included prominent investors such as Novo Holdings, OrbiMed, H.I.G. Capital, Quilvest Capital Partners, Covera Ventures, and Cariden Technologies. The company's slogan, "Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical trials with a focus on patient health and care," embodies its commitment to revolutionizing the field of oncology and prioritizing patient well-being and care. With its base in San Diego, California, Salmedix is carving a niche for itself in the Biotechnology and Health Care industries.

Business keywords: Oncology, Blood Cancers, Phase II Clinical Trials, Hematologic Malignancies, Drug Development, SDX-105, Healthcare Professionals, Germany, U.S., Canada, SDX-101, SDX-102, Clinical-Stage Product Candidates, David Kabakoff, San Diego

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $45.00M 6
Novo Holdings, OrbiMed +4
19 Oct 2005
Series B $27.50M 4
Aberdare Ventures, InterWest Partners +2
19 Jun 2002
Series A Undisclosed -
01 Jan 2001

Salmedix Alternatives & Competitors

View All Alternatives
Salmedix vs

Changing lives by changing the course of blood cancer.

Post-IPO Equity
356 employees
Biopharma, Biotechnology
Salmedix vs

Pioneering pharmaceuticals in the fight against blood cancers since 2000

Series A
1 employees
Biotechnology, Health Care
Salmedix vs

Adastra is committed to transforming cancer care.

Venture round
11-50 employees
Biotechnology, Health Care

FAQ About Salmedix

Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical trials with a focus on patient health and care
Salmedix was founded in 2000.
Salmedix operates in Biotechnology and Health Care. Its work centres on Oncology, Blood Cancers, Phase II Clinical Trials and Hematologic Malignancies.
Salmedix has completed 3 funding rounds, raising a total of $72.50M. The latest funding stage is Series C.
Top alternatives and competitors to Salmedix include Geron Corporation, LymphoSign, Adastra Pharmaceuticals, Syntara, Pacylex Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Salmedix and Geron Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Salmedix, https://bouncewatch.com/company/salmedix, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout